Fig. 3
From: Circulating EZH2-positive T cells are decreased in multiple sclerosis patients
Expression levels of EZH2 and TLN1 in treated multiple sclerosis patients. mRNA expression levels for EZH2 and TLN1 were determined by real-time PCR relative quantification in PBMC from untreated multiple sclerosis patients and patients receiving disease-modifying therapies for at least 1 year. Results are expressed as fold change (standard error of the mean) in gene expression in patients relative to controls. Statistics: Mann-Whitney U test. *p values < 0.001. UNT untreated patients, IFN interferon-beta, GA glatiramer acetate, FG fingolimod, NTZ natalizumab, EZH2 enhancer of zeste 2 polycomb repressive complex 2 subunit, TLN1 talin 1